| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BioNTech SE (NASDAQ: BNTX)
BNTX Technical Analysis
4
| As on 11th Jul 2025 BNTX STOCK Price closed @ 112.89 and we RECOMMEND Buy for LONG-TERM with Stoploss of 97.72 & Strong Buy for SHORT-TERM with Stoploss of 92.81 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BNTXSTOCK Price
| Open | 113.64 | Change | Price | % |
| High | 113.72 | 1 Day | -1.03 | -0.90 |
| Low | 112.06 | 1 Week | 5.38 | 5.00 |
| Close | 112.89 | 1 Month | 15.36 | 15.75 |
| Volume | 521910 | 1 Year | 13.99 | 14.15 |
| 52 Week High 126.88 | 52 Week Low 78.36 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NCNA | 0.05 | -16.67% |
| NVDA | 164.92 | 0.50% |
| OPEN | 0.78 | -11.36% |
| LMDX | 0.02 | 0.00% |
| HCTI | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| FTFT | 3.94 | 160.93% |
| SOFI | 21.20 | 1.10% |
| LCID | 2.29 | -1.72% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BNTX Daily Charts |
BNTX Intraday Charts |
Whats New @ Bazaartrend |
BNTX Free Analysis |
|
|
BNTX Important Levels Intraday
| RESISTANCE | 116.09 |
| RESISTANCE | 115.06 |
| RESISTANCE | 114.43 |
| RESISTANCE | 113.79 |
| SUPPORT | 111.99 |
| SUPPORT | 111.35 |
| SUPPORT | 110.72 |
| SUPPORT | 109.69 |
BNTX Forecast July 2025
| 4th UP Forecast | 136.57 |
| 3rd UP Forecast | 128.98 |
| 2nd UP Forecast | 124.28 |
| 1st UP Forecast | 119.59 |
| 1st DOWN Forecast | 106.19 |
| 2nd DOWN Forecast | 101.5 |
| 3rd DOWN Forecast | 96.8 |
| 4th DOWN Forecast | 89.21 |
BNTX Weekly Forecast
| 4th UP Forecast | 122.06 |
| 3rd UP Forecast | 119.12 |
| 2nd UP Forecast | 117.30 |
| 1st UP Forecast | 115.48 |
| 1st DOWN Forecast | 110.30 |
| 2nd DOWN Forecast | 108.48 |
| 3rd DOWN Forecast | 106.66 |
| 4th DOWN Forecast | 103.72 |
BNTX Forecast2025
| 4th UP Forecast | 218.8 |
| 3rd UP Forecast | 184.83 |
| 2nd UP Forecast | 163.84 |
| 1st UP Forecast | 142.84 |
| 1st DOWN Forecast | 82.94 |
| 2nd DOWN Forecast | 61.94 |
| 3rd DOWN Forecast | 40.95 |
| 4th DOWN Forecast | 6.98 |
BioNTech SE ( NASDAQ USA Symbol : BNTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BNTX Business Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Address: An der Goldgrube 12, Mainz, Germany, 55131
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service